Ignite Creation Date:
2024-10-26 @ 3:40 PM
Last Modification Date:
2024-10-26 @ 3:40 PM
Study NCT ID:
NCT06592222
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
None
First Post:
2024-08-08
Brief Title:
A Study to Learn About the Effectiveness of the Medicine Called Elranatamab in People With Relapsed Refractory Multiple Myeloma as Compared With Standard of Care Therapies
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Comparative Effectiveness of Elranatamab in Clinical Study C1071003 Versus Physicians Choice of Treatment PCT in Real-World RW External Control Arms in Patients With Triple-Class Refractory TCR Multiple Myeloma MM
Status:
ACTIVE_NOT_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is to understand how well elranatamab PF-06863135 may be used for relapsed refractory multiple myeloma RRMM Sometimes MM might improve at first but then gets resistant to the treatment and starts growing again known as relapsed refractory This study medicine will be compared with standard-of-care SOC therapies used in real-world clinical practice For people receiving elranatamab the investigators will use data from the phase 2 clinical trial MagnetisMM-3 The investigators will also use data from a real-world data source representing the SOC in clinical practice This study does not seek any participants for enrollment The investigators will compare the experiences of people receiving elranatamab to people receiving SOC therapies This way it will help the investigators to know how well elranatamab can be used for RRMM treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None